Suspended

Adipose Tissue, Isotope, and Flaxseed Oil Study in Retinitis Pigmentosa and Usher Syndrome Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Congenital Abnormalities+25

+ Abnormalities, Multiple

+ Blindness

See all eligibility criteria
How is the trial designed

Observational
Study Start: October 1999
See protocol details

Summary

Principal SponsorNational Center for Research Resources (NCRR)
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 1999

Actual date on which the first participant was enrolled.

PROTOCOL OUTLINE: Patients may participate in one or more of the arms of this study. Arm I (adipose tissue study): Adipose tissue is collected from the buttocks of patients with Usher II retinitis pigmentosa (RP), patients with non-Usher RP, and control subjects. Dietary histories are obtained from all patients and subjects. Arm II (isotope study): Patients meeting the same criteria as in arm I receive oral D5-labeled linolenic acid and oral D4-labeled linolenic acid that is dissolved in oil and incorporated into foods. Subjects must avoid eating fish and shellfish during the 35 days of the isotope study. Blood samples are collected at 0, 8, 24, and 48 hours, daily on days 3-7, and then on days 10, 18, and 35. Arm III (flaxseed oil feeding): Patients with all types of RP and control subjects receive flaxseed oil, a form of linolenic acid, for 12 weeks. Subjects may also receive high oleic safflower oil or olive oil as a control fat for 12 weeks. Subjects complete a diet history at the end of each fatty acid supplementation period. All subjects must follow a diet free of seafood and fish oil supplements.

NCT00004345
Principal SponsorNational Center for Research Resources (NCRR)
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Congenital AbnormalitiesAbnormalities, MultipleBlindnessDeafnessEar DiseasesEye DiseasesHearing DisordersHearing Loss, SensorineuralCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNervous System DiseasesNeurologic ManifestationsOtorhinolaryngologic DiseasesPathologic ProcessesRetinal DegenerationRetinal DiseasesSensation DisordersSigns and SymptomsPathological Conditions, Signs and SymptomsVision DisordersEye Diseases, HereditaryDisease AttributesGenetic Diseases, InbornHearing LossDeaf-Blind DisordersRetinal DystrophiesRetinitis PigmentosaRare DiseasesUsher Syndromes

Criteria

PROTOCOL ENTRY CRITERIA: Retinitis pigmentosa, including: Usher syndrome (types I and II) Simplex The following inheritance patterns eligible: X-linked recessive; Autosomal dominant; Autosomal recessive

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Oregon Health Sciences University

Portland, United StatesOpen Oregon Health Sciences University in Google Maps
SuspendedOne Study Center